NASDAQ:GMAB - Genmab A/S Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $41.57
Forecasted Upside: 11.48 %
Number of Analysts: 15
Breakdown:
2 Sell Ratings
4 Hold Ratings
9 Buy Ratings
0 Strong Buy Ratings

^$37.29 As of 05/10/2021 04:03 PM ET

▼ -0.11 (-0.29%)

1 month | 3 months | 12 months

Get New Genmab A/S Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for GMAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMAB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$41.57

▲ +11.48% Upside Potential

This price target is based on 15 analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is $41.57, with a high forecast of $49.00 and a low forecast of $36.00. The average price target represents a 11.48% upside from the last price of $37.29.

Hold

The current consensus among 15 investment analysts is to hold stock in Genmab A/S. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

11/16/2019

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

2/14/2020

0 strong buy ratings
7 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/14/2020

0 strong buy ratings
10 buy ratings
2 hold ratings
2 sell ratings

Ratings as of

8/12/2020

0 strong buy ratings
8 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

11/10/2020

0 strong buy ratings
8 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

2/8/2021

0 strong buy ratings
8 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

4/9/2021

0 strong buy ratings
9 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

5/9/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
4/26/2021	Morgan Stanley	Lower Price Target	Equal Weight	$41.00 ➝ $37.00	N/A	i
4/20/2021	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy		Low	i
4/19/2021	Morgan Stanley	Lower Price Target	Equal Weight	$41.00 ➝ $37.00	Low	i
3/15/2021	DNB Markets	Upgrade	Sell ➝ Buy		Low	i
3/9/2021	JPMorgan Chase & Co.	Reiterated Rating	Overweight		Low	i
3/9/2021	UBS Group	Reiterated Rating	Buy		Low	i
3/3/2021	SVB Leerink	Lower Price Target	Market Perform	$38.00 ➝ $36.00	Medium	i Rating by J. Chang at SVB Leerink LLC
2/25/2021	Truist	Boost Price Target		$42.00 ➝ $47.00	Low	i
2/25/2021	SVB Leerink	Lower Price Target	Market Perform	$38.00 ➝ $36.00	High	i Rating by J. Chang at SVB Leerink LLC
2/24/2021	Barclays	Reiterated Rating	Overweight		High	i
2/24/2021	Danske	Upgrade	Hold ➝ Buy		Medium	i
2/11/2021	HC Wainwright	Reiterated Rating	Buy		Low	i
1/26/2021	SVB Leerink	Boost Price Target	Market Perform	$34.00 ➝ $38.00	Medium	i Rating by J. Chang at SVB Leerink LLC
1/25/2021	DNB Markets	Downgrade	Hold ➝ Sell		Medium	i
1/19/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight		Low	i
1/15/2021	HC Wainwright	Boost Price Target	Buy	$44.00 ➝ $49.00	High	i
1/4/2021	Royal Bank of Canada	Boost Price Target	Positive ➝ Outperform	$40.00 ➝ $46.00	N/A	i
12/16/2020	Morgan Stanley	Boost Price Target	Overweight	$37.00 ➝ $41.00	Low	i
12/9/2020	SVB Leerink	Lower Price Target	Market Perform	$36.00 ➝ $34.00	Medium	i Rating by J. Chang at SVB Leerink LLC
11/25/2020	HC Wainwright	Lower Price Target	Buy	$45.00 ➝ $44.00	Low	i Rating by Ram Selvaraju at HC Wainwright
11/16/2020	UBS Group	Reiterated Rating	Buy		Low	i
11/5/2020	Morgan Stanley	Boost Price Target	Overweight	$35.00 ➝ $37.00	Low	i
11/5/2020	HC Wainwright	Boost Price Target	Buy	$42.00 ➝ $45.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
10/27/2020	The Goldman Sachs Group	Boost Price Target	Neutral	$37.00	High	i
10/13/2020	Morgan Stanley	Boost Price Target	Overweight	$32.00 ➝ $35.00	Low	i
9/23/2020	HC Wainwright	Boost Price Target	Buy	$41.00 ➝ $42.00	High	i Rating by Ram Selvaraju at HC Wainwright
9/23/2020	Bryan, Garnier & Co	Downgrade	Neutral ➝ Sell		High	i
9/8/2020	SVB Leerink	Initiated Coverage	Market Perform	$35.00	Low	i Rating by J. Chang at SVB Leerink LLC
8/24/2020	Truist	Boost Price Target		$39.00 ➝ $41.00	Low	i
8/21/2020	HC Wainwright	Boost Price Target	Buy	$40.00 ➝ $41.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
8/13/2020	Royal Bank of Canada	Boost Price Target	Outperform	$35.00 ➝ $38.00	Low	i
8/13/2020	Morgan Stanley	Boost Price Target	Overweight	$30.00 ➝ $32.00	High	i
8/13/2020	HC Wainwright	Reiterated Rating	Buy		High	i Rating by Ram Selvaraju at HC Wainwright
7/17/2020	HC Wainwright	Reiterated Rating	Buy	$40.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
7/2/2020	Societe Generale	Initiated Coverage	Sell		Low	i
6/30/2020	HC Wainwright	Reiterated Rating	Buy	$40.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
6/25/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral		Low	i
6/19/2020	Royal Bank of Canada	Boost Price Target	Outperform	$27.00 ➝ $35.00	Low	i
6/12/2020	JPMorgan Chase & Co.	Reiterated Rating	Overweight		Low	i
6/11/2020	Barclays	Reiterated Rating	Overweight		Low	i
6/11/2020	SunTrust Banks	Boost Price Target	Buy	$36.00 ➝ $39.00	Medium	i
6/11/2020	HC Wainwright	Boost Price Target	Buy	$34.00 ➝ $40.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
6/3/2020	Barclays	Reiterated Rating	Overweight		Medium	i
6/3/2020	Bryan, Garnier & Co	Downgrade	Buy ➝ Neutral		Low	i
6/2/2020	SunTrust Banks	Boost Price Target	Buy	$30.00 ➝ $36.00	Low	i
6/2/2020	Danske	Downgrade	Buy ➝ Hold		Low	i
6/1/2020	HC Wainwright	Reiterated Rating	Positive ➝ Buy	$29.00 ➝ $34.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
5/26/2020	UBS Group	Upgrade	Neutral ➝ Buy		Low	i
5/7/2020	SunTrust Banks	Boost Price Target	Buy	$28.00 ➝ $30.00	Low	i
5/7/2020	HC Wainwright	Boost Price Target	Buy	$28.00 ➝ $29.00	Low	i Rating by Ram Selvaraju at HC Wainwright
5/1/2020	HC Wainwright	Reiterated Rating	Buy	$28.00	High	i Rating by Ram Selvaraju at HC Wainwright
4/23/2020	Credit Suisse Group	Initiated Coverage	Outperform		Low	i
4/15/2020	Morgan Stanley	Lower Price Target	Overweight	$31.00 ➝ $30.00	Low	i
4/15/2020	HC Wainwright	Lower Price Target	Buy	$29.00 ➝ $28.00	Low	i Rating by Ram Selvaraju at HC Wainwright
4/6/2020	Royal Bank of Canada	Reiterated Rating	Buy	$27.00	Medium	i
3/4/2020	HC Wainwright	Reiterated Rating	Buy	$29.00	Low	i Rating by Ram Selvaraju at HC Wainwright
2/24/2020	HC Wainwright	Reiterated Rating	Buy	$25.00 ➝ $29.00	Low	i Rating by Ram Selvaraju at HC Wainwright
2/20/2020	Morgan Stanley	Boost Price Target	Overweight	$30.00 ➝ $31.00	Medium	i
2/11/2020	HC Wainwright	Reiterated Rating	Buy	$25.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
1/22/2020	HC Wainwright	Reiterated Rating	Buy	$25.00	Low	i Rating by Ram Selvaraju at HC Wainwright
1/13/2020	SunTrust Banks	Initiated Coverage	Buy		Medium	i
12/12/2019	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold		High	i
12/11/2019	HC Wainwright	Reiterated Rating	Buy	$25.00	High	i Rating by Ram Selvaraju at HC Wainwright
12/4/2019	HC Wainwright	Reiterated Rating	Buy	$25.00	Low	i Rating by Ram Selvaraju at HC Wainwright
11/20/2019	HC Wainwright	Reiterated Rating	Buy	$25.00	Low	i Rating by Ram Selvaraju at HC Wainwright
10/16/2019	HC Wainwright	Boost Price Target	Buy	$24.00 ➝ $25.00	Low	i Rating by Ram Selvaraju at HC Wainwright
9/27/2019	HC Wainwright	Set Price Target	Buy	$24.00	Low	i Rating by Ram Selvaraju at HC Wainwright
9/16/2019	HC Wainwright	Reiterated Rating	Buy	$24.00	Low	i Rating by R. Selvaraju at HC Wainwright
9/13/2019	Bank of America	Upgrade	Neutral ➝ Buy		Medium	i
9/12/2019	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$23.00	Low	i
8/26/2019	HC Wainwright	Reiterated Rating	Buy		Low	i Rating by R. Selvaraju at HC Wainwright
8/12/2019	Guggenheim	Initiated Coverage	Buy ➝ Buy		Medium	i
8/12/2019	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$23.00	Low	i
8/12/2019	Morgan Stanley	Initiated Coverage	Overweight ➝ Overweight		Low	i

(Data available from 5/10/2016 forward)

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Today's Range

Now: $37.29

$37.24

$37.72

50 Day Range

MA: $34.52

$31.65

$37.28

52 Week Range

Now: $37.29

$27.24

$44.83

Volume

9,593 shs

Average Volume

588,571 shs

Market Capitalization

$24.46 billion

P/E Ratio

28.91

Dividend Yield

N/A

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Genmab A/S?

The following Wall Street sell-side analysts have issued reports on Genmab A/S in the last year: Barclays PLC, Bryan, Garnier & Co, Credit Suisse Group AG, Danske, Deutsche Bank Aktiengesellschaft, DNB Markets, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, Societe Generale, SunTrust Banks, Inc., SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Truist, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for GMAB.

What is the current price target for Genmab A/S?

7 Wall Street analysts have set twelve-month price targets for Genmab A/S in the last year. Their average twelve-month price target is $41.57, suggesting a possible upside of 11.5%. HC Wainwright has the highest price target set, predicting GMAB will reach $49.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $36.00 for Genmab A/S in the next year.
View the latest price targets for GMAB.

What is the current consensus analyst rating for Genmab A/S?

Genmab A/S currently has 2 sell ratings, 4 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GMAB, but not buy more shares or sell existing shares.
View the latest ratings for GMAB.

What other companies compete with Genmab A/S?

Other companies that are similar to Genmab A/S include Zoetis, Bayer Aktiengesellschaft, Vertex Pharmaceuticals, Takeda Pharmaceutical, Regeneron Pharmaceuticals, Alexion Pharmaceuticals, Shiseido, Astellas Pharma, BeiGene, Takeda Pharmaceutical, Royalty Pharma, Genmab A/S, MERCK Kommanditgesellschaft auf Aktien, Horizon Therapeutics Public and UCB.

How do I contact Genmab A/S's investor relations team?

Genmab A/S's physical mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The company's listed phone number is 45-7020-2728 and its investor relations email address is [email protected] The official website for Genmab A/S is www.genmab.com.